MX2020004491A - Preparacion externa para tratar tinea unguium. - Google Patents
Preparacion externa para tratar tinea unguium.Info
- Publication number
- MX2020004491A MX2020004491A MX2020004491A MX2020004491A MX2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- properties
- external preparation
- efficacy
- aspects
- Prior art date
Links
- 208000002474 Tinea Diseases 0.000 title 1
- 206010067409 Trichophytosis Diseases 0.000 title 1
- 208000010195 Onychomycosis Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 abstract 2
- 229940057917 medium chain triglycerides Drugs 0.000 abstract 2
- 230000035699 permeability Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 201000005882 tinea unguium Diseases 0.000 abstract 2
- 230000000699 topical effect Effects 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 abstract 1
- 229960003937 efinaconazole Drugs 0.000 abstract 1
- 229940116333 ethyl lactate Drugs 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017209136 | 2017-10-30 | ||
| PCT/JP2018/040047 WO2019088005A1 (ja) | 2017-10-30 | 2018-10-29 | 爪白癬治療用の外用製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004491A true MX2020004491A (es) | 2020-08-13 |
Family
ID=66333195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004491A MX2020004491A (es) | 2017-10-30 | 2018-10-29 | Preparacion externa para tratar tinea unguium. |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220119363A (ko) | 2019-12-24 | 2022-08-29 | 가껭세이야꾸가부시기가이샤 | 에피나코나졸을 함유하는 의약 |
| KR102217617B1 (ko) * | 2020-08-14 | 2021-02-19 | 비엘엔에이치 주식회사 | 백선의 예방 또는 치료용 약학적 조성물 |
| JP2022547755A (ja) * | 2020-08-14 | 2022-11-16 | ビーエルアンドエイチ カンパニー，リミテッド | 白癬を防止又は処置するための医薬組成物 |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| CN119654156A (zh) | 2022-05-16 | 2025-03-18 | 玛路弘株式会社 | 白癣治疗用组合物 |
| TW202519215A (zh) * | 2023-08-02 | 2025-05-16 | 日商石原產業股份有限公司 | 甲癬用外用劑 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514385A (en) * | 1981-10-05 | 1985-04-30 | Alcon Laboratories, Inc. | Anti-acne compositions |
| JPS58162514A (ja) * | 1982-03-19 | 1983-09-27 | Sumitomo Chem Co Ltd | 外用ゲル製剤 |
| AU618517B2 (en) * | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
| WO1995009007A1 (en) * | 1993-09-29 | 1995-04-06 | Alza Corporation | Monoglyceride/lactate ester permeation enhancer for oxybutynin |
| EP1143950B1 (de) * | 1998-09-10 | 2005-03-09 | BioEqual AG | Topisch anwendbare mittel gegen nagelpilzerkrankungen |
| US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
| US8048919B2 (en) * | 2004-06-28 | 2011-11-01 | Archer Daniels Midland Company | Use of ethyl lactate as an excipient for pharmaceutical compositions |
| JP5061519B2 (ja) | 2006-07-12 | 2012-10-31 | 大正製薬株式会社 | 抗真菌剤含有ｏ／ｗエマルション組成物 |
| PL2191825T3 (pl) * | 2007-08-27 | 2016-11-30 | Środek przeciwko grzybiczemu zapaleniu skóry | |
| NL2003711C2 (en) * | 2009-10-27 | 2011-04-28 | Shield Mark B V | Aqueous composition for topical application, method of preparation, uses and device. |
| NL2003786C2 (en) * | 2009-11-11 | 2010-07-30 | Medner B V | COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS. |
| JP5362128B2 (ja) * | 2011-01-30 | 2013-12-11 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 外用抗真菌剤 |
| EP2773333B1 (en) * | 2011-11-04 | 2019-10-02 | Agile Therapeutics, Inc. | Dermal delivery compositions and methods |
| IN2015DN02377A (cg-RX-API-DMAC7.html) * | 2012-09-14 | 2015-09-04 | Pola Pharma Inc | |
| JP6869637B2 (ja) * | 2012-12-20 | 2021-05-12 | ビュシャン，ラジブ | 抗菌性組成物 |
| JP6308137B2 (ja) * | 2012-12-28 | 2018-04-11 | 大正製薬株式会社 | 皮膚適用製剤 |
| CN103142458B (zh) * | 2013-01-22 | 2015-09-09 | 莱普德制药有限公司 | 无成瘾性镇痛缓释递药系统的组方与制备方法 |
| CN112999223A (zh) * | 2013-11-22 | 2021-06-22 | 博世健康爱尔兰有限公司 | 抗感染的方法、组合物和装置 |
| JP5623671B1 (ja) * | 2014-07-23 | 2014-11-12 | 株式会社ポーラファルマ | ルリコナゾールを含有する製剤の評価方法及び指標物質 |
| MY195201A (en) * | 2015-09-18 | 2023-01-11 | Kaken Pharma Co Ltd | Biaryl Derivative and Medicine Containing Same |
| JP2017209136A (ja) | 2016-05-23 | 2017-11-30 | 澁谷工業株式会社 | 電子線殺菌装置 |
-
2018
- 2018-10-29 CN CN201880071260.4A patent/CN111295202B/zh not_active Expired - Fee Related
- 2018-10-29 RU RU2020117569A patent/RU2020117569A/ru unknown
- 2018-10-29 EP EP18872316.7A patent/EP3705136A4/en not_active Withdrawn
- 2018-10-29 KR KR1020207015246A patent/KR20200081432A/ko not_active Ceased
- 2018-10-29 SG SG11202003820VA patent/SG11202003820VA/en unknown
- 2018-10-29 BR BR112020008282-1A patent/BR112020008282A2/pt not_active IP Right Cessation
- 2018-10-29 TW TW107138191A patent/TWI789448B/zh not_active IP Right Cessation
- 2018-10-29 US US16/760,595 patent/US20210213002A1/en not_active Abandoned
- 2018-10-29 CA CA3081163A patent/CA3081163A1/en active Pending
- 2018-10-29 AU AU2018358372A patent/AU2018358372A1/en not_active Abandoned
- 2018-10-29 WO PCT/JP2018/040047 patent/WO2019088005A1/ja not_active Ceased
- 2018-10-29 JP JP2019529667A patent/JP6582158B1/ja active Active
- 2018-10-29 MX MX2020004491A patent/MX2020004491A/es unknown
-
2019
- 2019-09-02 JP JP2019159348A patent/JP2020011967A/ja active Pending
-
2020
- 2020-04-21 IL IL274100A patent/IL274100B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3705136A1 (en) | 2020-09-09 |
| TW201922247A (zh) | 2019-06-16 |
| KR20200081432A (ko) | 2020-07-07 |
| EP3705136A4 (en) | 2021-08-18 |
| IL274100B2 (en) | 2023-06-01 |
| WO2019088005A1 (ja) | 2019-05-09 |
| BR112020008282A2 (pt) | 2020-10-20 |
| RU2020117569A3 (cg-RX-API-DMAC7.html) | 2021-12-01 |
| US20210213002A1 (en) | 2021-07-15 |
| JP2020011967A (ja) | 2020-01-23 |
| SG11202003820VA (en) | 2020-05-28 |
| IL274100A (en) | 2020-06-30 |
| CA3081163A1 (en) | 2019-05-09 |
| JPWO2019088005A1 (ja) | 2019-11-14 |
| AU2018358372A1 (en) | 2020-05-28 |
| TWI789448B (zh) | 2023-01-11 |
| RU2020117569A (ru) | 2021-12-01 |
| CN111295202B (zh) | 2022-07-08 |
| JP6582158B1 (ja) | 2019-09-25 |
| CN111295202A (zh) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004491A (es) | Preparacion externa para tratar tinea unguium. | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| EP4234633A3 (en) | Wood preservative composition | |
| UY38160A (es) | Partículas implantables y métodos relacionados | |
| CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
| ECSP13013035A (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida | |
| EA202092586A1 (ru) | Ингибиторы magl | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| MX389697B (es) | Nuevos derivados de pirazolopirimidina. | |
| EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
| EA201991074A1 (ru) | Ингибиторы magl | |
| BR112019024566A2 (pt) | inibidores de pirazol magl | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA201790070A1 (ru) | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 | |
| EA202091003A1 (ru) | Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3 | |
| UY36447A (es) | Combinaciones de compuestos activos | |
| UY37306A (es) | Combinaciones de compuestos activos | |
| EP3586848A4 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A COMPOUND SUITABLE TO CROSS THE HEMATOENCEPHALIC BARRIER AS AN ACTIVE PRINCIPLE TO PREVENT OR TREAT BRAIN CANCER | |
| CR20170269A (es) | Combinaciones de compuestos activos | |
| CO2018001831A2 (es) | Composición de absorción percutánea en forma de parche | |
| EP3620457A4 (en) | COMPOUND DERIVED FROM PYRIMIDINE, OPTICAL ISOMER, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING A TYRO 3-RELATED DISEASE, CONSIDERING IT AS AN ACTIVE INGREDIENT | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. |